BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

ONC upcoming catalysts

BeOne Medicines: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 5 readout(s) and 1 FDA event(s). Subscribe to ONC (.ics).

Drugs: Zanubrutinib, Sonrotoclax, Tislelizumab, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide, Temozolomide, Fruquintinib, Zanidatamab, Lenvatinib, bendamustine, rituximab

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-31 est.P3BeOne Medicines ONCNCT04170283 A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutiniB-cell Malignanciesactive not recruiting955

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-05-13FDA approvalapprovedBEONE MEDICINES USA ONCBEQALZIApproved 2026-05-13: BEQALZI (NDA220711 ORIG1)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2BeOne Medicines ONCNCT06637501 A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemiaactive not recruiting94
2026-11 est.P1/P2BeOne Medicines ONCNCT04973605 A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, anRelapsed/Refractory Multiple Myelomarecruiting246
2026-09-22P2BeOne Medicines ONCNCT05952037 A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacrogloWaldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobuliactive not recruiting114
2026-05-23P3BeOne Medicines ONCNCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesAdvanced Malignanciescompleted404
2026-04-27P3BeOne Medicines ONCNCT04002297 A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell LymMantle Cell Lymphoma; Non-Hodgkin Lymphomaactive not recruiting510

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.